According to broker presentations, there was much interest from several intnl companies in SLT's Hep A rapid diagnostic, and there will be an announcement soon regarding the Hep A deal.
Further, SLT are working on a collaboration/licensing deal to expedite development of the Hep C rapid diagnostic.
With announcements that could catupolt SLT into a different league brewing in the next few weeks, it seems like downside risk is very small and upside potential is about to be realised.
Good time to get in and good luck to all holding.
SLT Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held
